| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc8b706fb22ca0baba35f66ce3e501ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f4538124fc66e683d2ae27e051cd4e4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-81 |
| filingDate |
2021-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b21203ca00384e74dbabed6eda71d304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f759195100a9317454b577a12d1db8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08e281cbe9b441c978bd251d0667b973
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_512d835f198a10a83b4e7e12f4ccfdfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77e243196aa06c2494e2f084425124d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_707ae47b7f2c94aaacd349a554596edc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6dc67a47e686e94bb5f90a68966ba1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8407e196e8c479e7e0451ae50476931
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa5a375287f5991d4184874221d5b764 |
| publicationDate |
2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021218884-A1 |
| titleOfInvention |
Use of aryl guanidine compound or pharmaceutically acceptable salt thereof |
| abstract |
The use of an aryl guanidine compound as represented by formula 1 or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating angiogenesis-related ophthalmic disorders. |
| priorityDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |